A Review on Unlocking the Theraputic Potential Effects of Semaglutide in Type 2 Diabetes and Obesity

The escalating prevalence of obesity and Type 2 Diabetes Mellitus posess a significant public health concern, necessitating innovative therapeutic strategies, mitigate complications and socioeconomic burdens. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has emerged as a transformative agent in the management of type 2 diabetes mellitus (T2DM) and obesity. Originally developed to improve glycemic control in T2DM, semaglutide has demonstrated significant benefits that extend beyond glucose regulation. Its mechanism of action involves enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite, collectively contributing to improved metabolic outcomes and substantial weight loss. Clinical trials have consistently shown that semaglutide not only lowers HbA1c levels but also facilitates meaningful reductions in body weight, positioning it as a dual-benefit therapy. Additionally, its cardiovascular safety profile and once-weekly administration improve patient adherence and quality of life. This review explores the pharmacological properties, clinical efficacy, safety considerations, and future prospects of semaglutide in managing T2DM and obesity. The growing body of evidence supports semaglutide’s role as a cornerstone in the therapeutic landscape of metabolic disorders, offering a promising strategy for addressing the global burden of diabetes and obesity.